Clinical trial · Interventional
Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas
Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors and Lymphomas
NCT00023166CI-TRIAL-00000075terminatedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Studies of PEG-paclitaxel have been terminated
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PEG-paclitaxel | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
None - Study has been terminated.
References
Publications (0)
Data not yet available
No reference posted for this study.